Related Experiment Videos
[Increased bone density in patients with multiple myeloma treated with clodronate]
Vnitrni Lekarstvi
|November 1, 1994
Summary
Clodronate therapy improved bone density and increased hydroxyapatite levels in myeloma patients over six months. This bisphosphonate treatment showed good tolerance, with careful calcium monitoring advised.
Area of Science:
- Oncology
- Pharmacology
- Bone Metabolism
Context:
- Bisphosphonates are indicated for hypercalcemia, but long-term use remains debated.
- Multiple myeloma patients often experience bone density loss and pain.
Purpose:
- To assess the impact of clodronate on bone density in multiple myeloma patients.
- Evaluate changes in hydroxyapatite levels and bone mineral density over six months.
Summary:
- Twenty myeloma patients received clodronate (3,000 mg total dose over 6 months).
- CT-densitometry showed increased hydroxyapatite in 9/15 patients; mean bone density improved from -2.6 to -2.3 SD.
- Mean hydroxyapatite increased from 32.71 to 38.91 mg/ml in trabecular bone.
Impact:
- Clodronate demonstrated a positive effect on bone density and hydroxyapatite content in myeloma patients.
- The drug was well-tolerated, with no renal impairment observed.
- Potential for improved bone health in myeloma management, with calcium monitoring crucial.